132 related articles for article (PubMed ID: 22351303)
21. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
[TBL] [Abstract][Full Text] [Related]
22. Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.
Westre B; Giske A; Guttormsen H; Wergeland Sørbye S; Skjeldestad FE
PLoS One; 2019; 14(11):e0221546. PubMed ID: 31689301
[TBL] [Abstract][Full Text] [Related]
23. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
24. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
[TBL] [Abstract][Full Text] [Related]
25. Rescreening Practices of Negative Papanicolaou Tests With Positive Human Papillomavirus Test Result.
Goyal A; Davey DD; Souers RJ; Tabbara SO; Goodrich K; Booth CN
Arch Pathol Lab Med; 2022 Jan; 146(1):78-83. PubMed ID: 33929528
[TBL] [Abstract][Full Text] [Related]
26. Should women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion, receive reflex human papillomavirus-DNA testing?
Liman AK; Giampoli EJ; Bonfiglio TA
Cancer; 2005 Dec; 105(6):457-60. PubMed ID: 16104044
[TBL] [Abstract][Full Text] [Related]
27. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
[TBL] [Abstract][Full Text] [Related]
28. Team Reading (Peer Review) of Suspicious/Positive Slides for Continuous Quality Improvement in Cervical-Vaginal Cytology: A Comparison between Methods and Indicators.
Placidi A; Capparucci P; Di Luzio A; Manca G; Mania E; Filippini T; Giorgi Rossi P
Acta Cytol; 2016; 60(5):458-464. PubMed ID: 27504992
[TBL] [Abstract][Full Text] [Related]
29. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
30. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
31. Reflex high-risk human papilloma virus DNA test is useful in the triage of women with atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion.
Wu HH; Allen SL; Kirkpatrick JL; Elsheikh TM
Diagn Cytopathol; 2006 Oct; 34(10):707-10. PubMed ID: 16955480
[TBL] [Abstract][Full Text] [Related]
32. An analysis of human papillomavirus testing and endocervical component on pap tests: A pilot study using the Roche Cobas(®) assay.
Pierce KJ; Currens HS; Tafe LJ; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2016 Apr; 44(4):280-2. PubMed ID: 26801205
[TBL] [Abstract][Full Text] [Related]
33. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
34. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303
[TBL] [Abstract][Full Text] [Related]
35. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
[TBL] [Abstract][Full Text] [Related]
36. Correlation of Pap smear, cervical biopsy, and clinical follow-up with an HPV typing microarray system.
Nuovo GJ; Bartholomew D; Jung WW; Han IK; Um T; Grabarz DF; Lee DJ; McCabe RT
Diagn Mol Pathol; 2008 Jun; 17(2):107-11. PubMed ID: 18382353
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of liquid-based Pap tests: comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal Pap smears.
Guo M; Hu L; Martin L; Liu S; Baliga M; Hughson MD
Acta Cytol; 2005; 49(2):132-8. PubMed ID: 15839615
[TBL] [Abstract][Full Text] [Related]
38. Significance and possible causes of false-negative results of reflex human Papillomavirus infection testing.
Eltoum IA; Chhieng DC; Crowe DR; Roberson J; Jin G; Broker TR
Cancer; 2007 Jun; 111(3):154-9. PubMed ID: 17477380
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and typing of HPV DNA by hybrid capture II in women with ASCUS, ASC-H, LSIL, and AGC on ThinPrep Pap tests.
Rowe LR; Aldeen W; Bentz JS
Diagn Cytopathol; 2004 Jun; 30(6):426-32. PubMed ID: 15176032
[TBL] [Abstract][Full Text] [Related]
40. Inter-laboratory variability in the presence of human papillomavirus in normal and abnormal cervical cytology samples.
Weyn C; Garbar C; Noël JC; Weynand B; Verhest A; d'Olne D; Arbyn M; Englert Y; Fontaine V
Cancer Epidemiol; 2013 Aug; 37(4):457-61. PubMed ID: 23628128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
